Skip to main content
Premium Trial:

Request an Annual Quote

George Poste, Brian Ward, Stella Quan

Premium
George Poste is taking on the role of non-executive vice chairman and chief scientific advisor of CDX Holdings, the parent company of Caris Diagnostics and Caris Molecular Diagnostics. Poste also has been named non-executive chairman of Caris Molecular Diagnostics. He has been a director of Caris Diagnostics since November 2006.
 
Poste is chief scientist of the Complex Adaptive Systems Initiative and director of The Biodesign Institute at Arizona State University. He also is CEO of Health Technology Networks. Between 1992 and 1999, Poste was chief science and technology officer and president of R&D at SmithKline Beecham, prior to its merger with Glaxo Wellcome.
 

 
The DNA Repair Company has appointed Brian Ward to be executive VP and it has named Stella Quan to be senior director of product development. Ward formerly was senior VP for Genomic Health. He also has served as president of medical genetic services and senior vice president of operations at Myriad Genetic Laboratories, and he has worked at Genzyme Genetics and at the University of Colorado.
 
Quan was director of immunoassay development for BioMérieux, was senior director of operations at Tripath Oncology, and she was involved in research and development at Chiron.

Filed under

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.